NEW YORK (GenomeWeb) – Mirati Therapeutics is studying a number of personalized medicine cancer drugs, for which it is planning to use next-generation sequencing platforms to interrogate complex genetic markers associated with patient response. Ultimately, if these programs are successful, the company hopes to launch the drugs alongside NGS-based companion diagnostics, according to company executives.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.